GENA-119B31 / Genome & Company - LARVOL DELTA

Targeting APP with GENA-119B31: A novel approach to overcoming immune checkpoint inhibitor resistance in cancer immunotherapy (AACR 2025) - "This study confirms the potential of APP as a target for cancer immunotherapy through the use of the anti-APP antibody GENA-119B31. Our findings provide preclinical evidence supporting GENA-119B31 as a promising novel therapeutic strategy."

Checkpoint inhibition • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • ACTN4 • APP • CD4 • CD8 • CNTN • IFNG